Enoxaparin sodium biosimilar (Fresenius Kabi)

N/A

Report date: 2024/03/26 16:54:08

Base Information

Drug NameEnoxaparin sodium biosimilar (Fresenius Kabi)
Drug Alias NameELONOXELONOX HP
ClassificationNatural product/Extract > Animal extractBiologics > Biosimilar
Mechanisms of ActionAntithrombin-III activatorsThrombin inactivationFactor Xa inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsVenous ThrombosisThromboembolism
Global Approved IndicationsVenous ThrombosisThromboembolism
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2022/10/26
Country/TerritoryCanada
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesFresenius Kabi Canada Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFresenius Kabi Canada Ltd
Inactive CompaniesN/A
Active IndicationsVenous ThrombosisThromboembolism
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A